Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92211Research ArticleBessimptomnyy ateroskleroz pri arterial'noy gipertonii: naskol'ko effektivnymi v etoy situatsii mogut okazat'sya ingibitory APF?LopatinYu. M-15112006811303528122021Copyright © 2006, Consilium Medicum2006артериальная гипертензияантигипертензивные препаратыатеросклероз[Ezzati M, Lopez A.D, Rodgers A et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–60.][Thomas F, Rudnichi A, Bacri A.M et al. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001; 37: 1256–61.][Kannel W.B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13 (1 Pt 2): 3S–10S.][Thomas F, Beah K, Guize L et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002; 23: 528–35.][Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Прил. к журн. "Кардиоваскул. тер. и профилак.", 2004.][Kuulasmaa K, Tunstall-Pedoe H, Dobson A et al. Estimation of contribution of changes in classic risk factors to trends in coronary - event rates across the WHO MONICA Project populations. Lancet 2000; 355: 675–87.][Crouse J.R. III. Imaging atherosclerosis: state of art. J Lipid Res 2006; 47: 1677–99.][Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.][2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.][Bots M.L, Hoes A.W, Koudstaal P.J et al. Common carotid intima - media thickness and risk of stroke and myocardial infarction. The Rotterdam Study. Circulation 1997; 96: 1432–7.][Burke G.L, Evans G.W, Riley W.A et al. for the ARIC Study Group: Arterial wall thickness is associated with prevalent cardiovascular diseases in middle - aged adults. The Atherosclerosis Risk in Communities (ARIC) study. Stroke 1995; 26: 386–91.][Favre A, Monpere C, Voyer C et al. How to improve primary prevention in asymptomatic high risk subjects? Eur Heart J 2004; 6 (suppl. J): J59–63.][Wang Ji-G, Staessen J.A, Li Y et al. Carotid intima - media thickness and antihypertensive treatment: a meta - analysis of randomized controlled trials. Stroke 2006; 37: 1933–40.][Dahlof B et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumetiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial_Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.][National Institute of Clinical Excellence (NICE). Hypertension: management of hypertension in adults in primary care (partial update). June 2006; 45P.][Migdalis I.N, Gerolimou B, Kozanidou G et al. Effect of fosinopril sodium on early carotid atherosclerosis in diabetic patients with hypertension. J Med 1997; 28: 371-80.][Lonn E.M, Yusuf S, Dzavik V et al. for the SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis. The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919–25.][The Heart Outcomes Prevention Evaluation study Investigators. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high - risk patients. N Engl J Med 2000; 342: 145–53.][Mac Mahon S, Sharpe N, Gamble G et al. Randomized, placebo - controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or occlusive arterial disease. J Am Coll Cardiol 2000; 36: 438–43.][Cashin-Hemphill L, Homvang G, Chan R.C et al. Angiotensin - converting enzyme inhibition as antiatherosclerotic therapy: no answer yet: Quinapril Ischemic Event Trial. Am J Cardiol 1999; 83: 43–7.][Teo K.K, Burton J.R, Buller C.E et al. Long term effects of cholesterol lowering and angiotensin - converting enzyme inhibition on coronary artherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748–54.][Zanchetti A, Crepaldi G, Bond M.G et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS – a randomized double - blind trial. Stroke 2004; 35: 2807–12.][Zanchetti A, Agabiti-Rosei E, Dal Palu C et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long - term randomized treatment with either verapamil or chlorthalidone on carotid intima - media thickness. J Hypertens 1998; 16: 1667–76.][Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co - amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949–54.][Zanchetti A, Bond M.G, Hennig M et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double - blind, long - term trial. Circulation 2002; 106: 2422–7.]